BUFFALO, NY- July 19, 2024 – A new research perspective was published in Oncoscience (Volume 11) on May 23, 2024, entitled, “Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.”
In this perspective, researchers Joseph R. Testa, Yuwaraj Kadariya, and Joseph S. Friedberg from Fox Chase Cancer Center in Philadelphia, Pennsylvania, identify potential targets for mesothelioma prevention. Mesothelioma, an incurable cancer of the mesothelial lining, is often caused by exposure to asbestos. Asbestos-induced inflammation is a significant contributing factor in the development of mesothelioma, and genetic factors also play a role in the susceptibility to this rapidly progressive and treatment-resistant malignancy.
Consequently, novel approaches are urgently needed to treat mesothelioma and prevent or reduce the overall incidence of this fatal disease.
Credit: N/A
BUFFALO, NY- July 19, 2024 – A new research perspective was published in Oncoscience (Volume 11) on May 23, 2024, entitled, “Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.”
In this perspective, researchers Joseph R. Testa, Yuwaraj Kadariya, and Joseph S. Friedberg from Fox Chase Cancer Center in Philadelphia, Pennsylvania, identify potential targets for mesothelioma prevention. Mesothelioma, an incurable cancer of the mesothelial lining, is often caused by exposure to asbestos. Asbestos-induced inflammation is a significant contributing factor in the development of mesothelioma, and genetic factors also play a role in the susceptibility to this rapidly progressive and treatment-resistant malignancy.
Consequently, novel approaches are urgently needed to treat mesothelioma and prevent or reduce the overall incidence of this fatal disease.
“In this research perspective, we review the current state of chemoprevention and cancer interception progress in asbestos-induced mesothelioma.”
The researchers also discuss the different preclinical mouse models used for these investigations and the inflammatory factors that may be potential targets for mesothelioma prevention. Preliminary studies with naturally occurring phytochemicals and synthetic agents are reviewed. Results of previous clinical chemoprevention trials in populations exposed to asbestos and considerations regarding future trials are also presented.
Continue reading: DOI: https://doi.org/10.18632/oncoscience.605
Correspondence to: Joseph R. Testa
Email: [email protected]
Keywords: asbestos, Bap1 mutations, chemoprevention agents, inflammation, preclinical genetically engineered mouse models
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
Oncoscience is indexed and archived by PubMed, PubMed Central, Scopus, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
- X, formerly Twitter
- YouTube
For media inquiries, please contact [email protected].
Oncoscience Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
Journal
Oncoscience
DOI
10.18632/oncoscience.605
Method of Research
Content analysis
Subject of Research
Animals
Article Title
Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma
Article Publication Date
23-May-2024
COI Statement
JRT reports a patent on BAP1 mutation testing and has provided legal consultation regarding the role of genetic alterations in mesothelioma. The other authors have no conflicts to declare.
